Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Enhanced CD33 CAR-NK cells secreting anti-CD73scFv overcome adenosine-mediated immunosuppression and improve anti-AML efficacy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmra1406184
10.1056/nejmra1406184 · External reference
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
10.1002/ajh.27625 · 2025 · External reference
Current status and research directions in acute myeloid leukemia
10.1038/s41408-024-01143-2 · 2024 · External reference
Cellular therapy for acute myeloid Leukemia - Current status and future prospects
10.1016/j.blre.2019.05.002 · 2019 · External reference
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
10.1016/s0140-6736(14)61403-3 · 2015 · External reference
10.1038/s41375-021-01253-x
10.1038/s41375-021-01253-x · External reference
10.1186/s13045-020-00910-5
10.1186/s13045-020-00910-5 · External reference
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization
10.1038/s41392-024-02005-w · 2024 · External reference
10.1038/s41571-020-0426-7
10.1038/s41571-020-0426-7 · External reference
CAR-NK cells for cancer immunotherapy: recent advances and future directions
10.3389/fimmu.2024.1361194 · 2024 · External reference
10.1186/s13045-021-01083-5
10.1186/s13045-021-01083-5 · External reference
10.1038/leu.2017.226
10.1038/leu.2017.226 · External reference
10.1182/blood-2011-12-398370
10.1182/blood-2011-12-398370 · External reference
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
10.1186/s40164-024-00592-6 · 2025 · External reference
10.1038/leu.2015.52
10.1038/leu.2015.52 · External reference
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
10.1136/jitc-2021-003149 · 2021 · External reference
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing
10.1172/jci162593 · 2024 · External reference
10.1038/s41408-022-00660-2
10.1038/s41408-022-00660-2 · External reference
Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia
10.1016/j.canlet.2023.216103 · 2023 · External reference
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
10.1038/s41467-024-52388-1 · 2024 · External reference
A novel feeder cell based on 4-1BBL and membrane-bound IL-21/IL-15 induce highly expansion and anti-tumor effect of natural killer cells
10.1186/s12896-025-01024-x · 2025 · External reference
10.1172/jci128895
10.1172/jci128895 · External reference
10.1038/nrc.2017.86
10.1038/nrc.2017.86 · External reference
Adenosine in cancer immunotherapy: Taking off on a new plane
10.1016/j.bbcan.2023.189005 · 2023 · External reference
Downregulation of CD73 associates with T cell exhaustion in AML patients
10.1186/s13045-019-0728-3 · 2019 · External reference
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
10.3389/fimmu.2016.00109 · 2016 · External reference
10.1158/0008-5472.can-17-2826
10.1158/0008-5472.can-17-2826 · External reference
10.3389/fimmu.2019.00925
10.3389/fimmu.2019.00925 · External reference
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
10.3389/fimmu.2023.1212209 · 2023 · External reference
Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
10.1186/s40425-018-0441-8 · 2018 · External reference
10.1016/j.celrep.2019.04.091
10.1016/j.celrep.2019.04.091 · External reference
10.1007/s00262-011-1040-4
10.1007/s00262-011-1040-4 · External reference
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
10.1136/jitc-2020-001689 · 2020 · External reference
Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML
10.1080/2162402x.2021.1930391 · 2021 · External reference
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
10.1126/sciadv.aaw4304 · 2019 · External reference
10.1007/s11302-020-09760-9
10.1007/s11302-020-09760-9 · External reference
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
10.1186/s12967-020-02285-0 · 2020 · External reference
10.1056/nejmoa1910607
10.1056/nejmoa1910607 · External reference
CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia
10.1136/jitc-2025-011887 · 2025 · External reference
10.1186/s12943-023-01733-x
10.1186/s12943-023-01733-x · External reference
